News
-
In a November 5, 2013 interview on CNBC, Acorda CEO Ron Cohen announced that the company has filed a regulatory application to the FDA for its diazepam nasal spray for the treatment of epilepsy. Acorda… Read more . . .
-
Novartis has announced that “it will initiate consultation on proposals to close” its respiratory R&D center in Horsham, UK. According to Novartis, the potential closing will affect “up to 371 roles” at the site, plus… Read more . . .
-
The US FDA has issued a warning letter to Sunovion regarding claims made in four patient brochures aimed respectively at COPD patients currently using MDIs, DPIs, nebulized short acting beta agonists, or any medication giving… Read more . . .
-
Copley Scientific‘s new TPK-R critical flow controller is designed specifically to connect to the right-hand outlet of NGI cascade impactor, allowing for efficient use of bench space, the company says. The TPK-R is a mirror… Read more . . .
-
Health Canada has approved Almirall’s Tudorza Genuair aclidinium bromide DPI for the treatment of COPD, Almirall Canada has announced. Forest Laboratories is partnered with Almirall on commercialization of the product in Canada and in the… Read more . . .
-
GlaxoSmithKline and Theravance have announced the availability of the Breo Ellipta fluticasone furoate/vilanterol DPI in the US. The FDA approved Breo Ellipta for the treatment of COPD in May 2013. The launch triggers a $30… Read more . . .
-
MannKind, which resubmitted its NDA for Afrezza inhaled insulin earlier this month, has announced that, “The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in… Read more . . .
-
Bend Research has added an Xcelodose 600S powder micro-dosing system, the company said, allowing it to fill capsules for inhalation development projects with low dose weights. The company notes that, “Precision capsule fill capability is… Read more . . .
-
MDI component manufacturer Presspart has announced a round of changes to its management team. According to the company, Hans Neugebauer, who is currently Managing Director of Presspart Marsberg, will become Managing Director of Presspart Blackburn… Read more . . .
-
Canadian cardiovascular drug development company Milestone Pharmaceuticals has initiated a Phase 1 clinical trial of its lead product, MSP-2017 intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT), the company announced.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland